Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

ASH 2024

Leukemia

Quizartinib significantly reduces relapse rates versus midostaurin in newly diagnosed patients with FLT3-ITD-positive AML, based on MAIC analysis

ASH 2024

Leukemia

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

Leukemia

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Blood

Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB

doi: 10.1182/blood.2024025154

ASCO 2024

Genitourinary Cancer

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Leukemia

Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood

Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, Gilkes AF, Thomas I, Johnson S, Canham J, Cavenagh JD, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett AK, Wilhelm-Benartzi CS, Dilon R, Russell NH

doi: 10.1182/blood.2023023096

SPECIAL REPORT

Lymphoma

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

ASCO 2024

Genitourinary Cancer

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

ASCO 2024

Genitourinary Cancer

Related content

Quizartinib significantly reduces relapse rates versus midostaurin in newly diagnosed patients with FLT3-ITD-positive AML, based on MAIC analysis

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Real-World Comparison of YESCARTA® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Real-world study: Apalutamide achieved improved deep, early PSA response versus enzalutamide in patients with de novo mHSPC

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement